» Articles » PMID: 31291138

Metastatic Breast Cancer in Kenya: Presentation, Pathologic Characteristics, and Patterns-Findings From a Tertiary Cancer Center

Overview
Journal J Glob Oncol
Specialty Oncology
Date 2019 Jul 11
PMID 31291138
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The purpose of this research was to describe the sociodemographic and clinical characteristics of Kenyan women with metastatic breast cancer diagnosed and treated at Aga Khan University Hospital in Nairobi, Kenya from 2012 to 2018.

Patients And Methods: We reviewed charts of Kenyan women with metastatic breast cancer and analyzed sociodemographic data, breast cancer risk factors, and tumor characteristics associated with stage at diagnosis, receptor status (ie, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 [HER2]), and site of metastasis using χ, analysis of variance, two-sample tests, and logistic regressions.

Results: A total of 125 cases with complete medical records were included in the analysis. Forty women (32%) had metastases at diagnosis. Of the others, those diagnosed in stage III developed metastases sooner than those diagnosed in stage II ( < .001). Fifty-eight percent of patients had metastases to bone, 14% to brain, 57% to lungs, and 50% to liver. Seventy-four percent of patients presented with more than one metastatic site. Metastases to bone were associated with greater age at diagnosis ( = .02) and higher parity ( = .04), and metastases to the brain were associated with early menopause ( = .04), lower parity ( = .04), and lack of breastfeeding ( = .01). Patients whose tumors were triple negative (estrogen receptor-negative, progesterone receptor-negative, and HER2 negative) were more likely to develop brain metastases ( = .01), and those whose tumors were HER2 positive were more likely to develop liver metastases ( = .04).

Conclusion: Although our data on patterns of metastases and pathologic subtypes are similar to those in published literature, some unique findings concerning hormonal risk factors of women with metastatic breast cancer and specific metastatic sites need additional exploration in larger patient populations.

Citing Articles

Breast cancer molecular subtype classification according to immunohistochemistry markers and its association with pathological characteristics among women attending tertiary hospitals in Tanzania.

Ismail A, Panjwani S, Ismail N, Ngimba C, Mosha I, Adebayo P Heliyon. 2024; 10(19):e38493.

PMID: 39398050 PMC: 11466674. DOI: 10.1016/j.heliyon.2024.e38493.


Immunohistochemistry-derived subtypes of breast cancer distribution in four regions of Ethiopia.

Belachew E, Desta A, Gebremariam T, Deneke D, Ashenafi S, Yeshi M Front Endocrinol (Lausanne). 2023; 14:1250189.

PMID: 38027092 PMC: 10666628. DOI: 10.3389/fendo.2023.1250189.


Population-specific Mutation Patterns in Breast Tumors from African American, European American, and Kenyan Patients.

Tang W, Zhang F, Byun J, Dorsey T, Yfantis H, Ajao A Cancer Res Commun. 2023; 3(11):2244-2255.

PMID: 37902422 PMC: 10629394. DOI: 10.1158/2767-9764.CRC-23-0165.


Different risk and prognostic factors for liver metastasis of breast cancer patients with and relapsed distant metastasis in a Chinese population.

Zhang N, Xiang Y, Shao Q, Wu J, Liu Y, Long H Front Oncol. 2023; 13:1102853.

PMID: 37124528 PMC: 10146248. DOI: 10.3389/fonc.2023.1102853.


Treatment outcomes and its associated factors among breast cancer patients at Kitui Referral Hospital.

Wambua M, Degu A, Tegegne G SAGE Open Med. 2022; 10:20503121211067857.

PMID: 35024144 PMC: 8744162. DOI: 10.1177/20503121211067857.


References
1.
Slaoui M, Razine R, Ibrahimi A, Attaleb M, El Mzibri M, Amrani M . Breast cancer in Morocco: a literature review. Asian Pac J Cancer Prev. 2014; 15(3):1067-74. DOI: 10.7314/apjcp.2014.15.3.1067. View

2.
Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013. DOI: 10.1200/JCO.2013.50.9984. View

3.
DeSantis C, Fedewa S, Sauer A, Kramer J, Smith R, Jemal A . Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2015; 66(1):31-42. DOI: 10.3322/caac.21320. View

4.
Stampfli S, Akhmedov A, Hausladen S, Varga Z, Dedes K, Hellermann J . Tissue Factor Expression Does Not Predict Mortality in Breast Cancer Patients. Anticancer Res. 2017; 37(6):3259-3264. DOI: 10.21873/anticanres.11689. View

5.
Westhoff C, Pike M . Hormonal contraception and breast cancer. Am J Obstet Gynecol. 2018; 219(2):169.e1-169.e4. PMC: 6764434. DOI: 10.1016/j.ajog.2018.03.032. View